

Contact: Julie Miller
Phone: 310-437-0544, Ext. 179
Email: julie@sages.org



FOR IMMEDIATE RELEASE

The SINC Fund Has Made an Investment in Surgical Device Company NeXtGen™ Biologics

June 27, 2024 - Los Angeles, Calif. – The SINC Fund, a venture capital fund sponsored by SAGES Ingenuity Inc. (<https://www.sages-ingenuity.com>), a for-profit entity formed to invest in and accelerate innovation, and Varia Ventures Management Company, LLC (<https://www.varia.com>), a venture capital firm, are pleased to announce an investment in NeXtGen™ Biologics Inc. (<https://www.nextgenbiologics.com/about.html>), an innovative medical device company focusing on advanced wound care.

NeXtGen Biologics owns a suite of patents encompassing extracellular matrix (ECM) platform solutions designed to treat and better manage a myriad of complex conditions seen in wounds, general surgery, trauma, plastic surgery, cardiovascular diseases, neurosurgery, orthopedics and ophthalmology.

“FDA clearance of NeoMatrix® Wound Matrix, and coverage by Medicare representing more than 65 million lives are important milestones propelling NeXtGen in providing physicians with a novel platform solution for patients who suffer from a wide variety of wounds,” said Jonelle Toothman, NeXGen Biologics’ chief executive officer.

“The SINC Fund is excited to invest into a company that harnesses the potential of the Axolotl, with its associated regenerative abilities, and what it brings to the (OR) table,” said SD Schweitzberg, MD, FACS, Chair of the SINC Fund Investment Committee.

The SINC Fund (<https://sincinvest.varia.com/>) was launched to give SAGES members and others the opportunity to diversify their portfolios by investing in a venture fund with a portfolio of startups primarily in the therapeutic GI/GI surgery space. NeXtGen Biologics is the second investment for the SINC Fund, with several additional investments pending upon completion of due diligence. The SINC Fund is still open to investors, with a fund closing date targeted for August. If you are interested in learning more and potentially investing, please visit <https://www.varia.com/sinc>.

About SAGES

The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) is a leading surgical society representing a global community of more than 7,000 surgeons bringing minimal access surgery and emerging techniques to patients worldwide. SAGES mission is to innovate, educate

and collaborate to improve patient care with a vision of reimagining surgical care for a healthier world. For more information, go to <https://www.sages.org>.

About Varia Ventures

Varia is a venture capital firm that partners globally recognized thought leaders, prestigious medical and surgical societies and others to manage venture funds in their fields of expertise.

About NeXtGen Biologics

Each year, approximately 12 million U.S. patients suffer traumatic lacerations, and 250 million people worldwide undergo surgical incisions. Chronic wounds affect 6.5 million people in the U.S., often leading to scarring, adhesions, incomplete healing, and infection. Despite technological advancements, surgical and chronic wounds remain problematic, with no product achieving scar-free healing. NeXtGen is exploring the axolotl's regenerative abilities to develop the NeoMatriX® Wound MatriX, which received FDA clearance in 2018 and 2021. NeoMatriX® shows promising results in treating difficult-to-heal wounds and is available in various forms, with Medicare coverage in multiple healthcare settings.

¹Block, et al Adv. Wound Care Oct 1; 4, 607–614 (2015) ²Sen, et al Wound Repair Regen. 2009; 17(6): 763-771 ³<http://sitn.hms.harvard.edu/flash/2018/regeneration-axolotl-can-teach-us-regrowing-human-limbs/> ⁴Internal Data

Disclaimer:

None of SAGES, SAGES Ingenuity, Varia Ventures or any of their affiliates provides personalized advice about investments, and this content should not be construed or relied on as such. You should consult your own advisers concerning any investment. All content is for informational purposes only. This content does not constitute an offer to sell, or a solicitation of an offer to buy, an interest in any jurisdiction in which it unlawful to make such an offer or solicitation. Offers of securities are made only to accredited investors pursuant to a fund's offering documents, which describe the risks, fees and other information that should be considered before investing. This content may contain forward-looking statements, which should not be relied upon and are not guarantees of future results, performance, achievements or success. Certain information contained herein has been obtained from other parties. While such sources are believed to be reliable, none of SAGES, SAGES Ingenuity, Varia Ventures or any of their affiliates assumes any responsibility for the accuracy or completeness of such information. The information set forth herein does not purport to be complete and no obligation to update or otherwise revise such information is being assumed.